3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)

Source The Motley Fool

Key Points

  • AbbVie is a Dividend King that has proven its resilience.

  • Enbridge appears to have a straightforward path to delivering double-digit total returns.

  • Realty Income offers a highly reliable dividend plus attractive growth potential.

  • 10 stocks we like better than AbbVie ›

The best investing strategies aren't always the most complicated ones. Sometimes, simply buying great dividend stocks and holding them for the long term is the smartest approach you can take.

Of course, you have to find the right stocks. While there are many great candidates, here are three dividend stocks that I think are great picks to buy and hold forever.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

Hands next to a laptop with the word "Dividend" and digital images of currency symbols displayed above the laptop.

Image source: Getty Images.

1. AbbVie

Perhaps the most important thing to know about AbbVie (NYSE: ABBV) is that it's a Dividend King. This elite group of companies have increased their dividends for at least 50 consecutive years. AbbVie's track record of dividend hikes spans 53 straight years, including the period when it was part of Abbott Labs (NYSE: ABT).

Inclusion in the Dividend Kings usually means that a company has a remarkably resilient underlying business. That's definitely the case with AbbVie. Its roots date back to 1888. The company has survived and thrived throughout its 138-year history despite facing stiff challenges.

One of AbbVie's biggest challenges was the patent expiration for Humira, which ranked for years as its top-selling product. But management planned well for the loss of exclusivity. Today, AbbVie has two successors to Humira -- Skyrizi and Rinvoq -- that together are already more successful than Humira was at its peak.

AbbVie's business development strategy has also been effective. Most recently, the company announced plans to acquire Apogee Therapeutics for $10.9 billion. This deal further expands AbbVie's immunology pipeline.

2. Enbridge

Enbridge (NYSE: ENB) isn't a Dividend King yet, but it's well on the way to joining the club. The energy company has increased its dividend for 31 consecutive years. And with a dividend yield of around 5.6%, Enbridge doesn't need to deliver tremendous share price appreciation to deliver a double-digit total return.

I think such attractive returns are likely going forward. Four key trends serve as big growth drivers for Enbridge: the surging build-out of data centers, rising demand for liquid natural gas (LNG), onshoring, and the conversion of power plants from coal to gas.

Enbridge forecasts a compound annual growth rate of around 5% for its distributable cash flow, earnings per share, and earnings before interest, taxes, depreciation, and amortization (EBITDA). As long as the company's dividends continue to flow at least at current levels, double-digit total returns should be attainable.

Fortunately for investors, Enbridge's business stability should make the dividend safe. The company operates the world's longest oil and liquids transportation system, with its pipelines transporting 40% of U.S. crude oil imports and 30% of crude oil produced in North America. It's also North America's largest natural gas utility by volume.

3. Realty Income

Speaking of business stability, the third dividend stock on our list ranks highly in this category. Realty Income (NYSE: O) shares have outperformed the S&P 500 (SNPINDEX:^GSPC) across 13 drawdowns of 10% or more since its public listing in 1994, with an average total return of -2.6% versus -22.6% for the S&P 500.

The real estate investment trust (REIT) has also increased its dividend for 31 consecutive years. And it has paid a dividend for 674 consecutive months.

What's behind Realty Income's remarkable record? A diversified real estate portfolio serves as a key factor. The REIT owns over 15,500 properties leased to clients representing 92 industries. Those industries include recession-resistant ones, such as grocery stores, convenience stores, and dollar stores.

Realty Income's growth prospects look bright, too. The company has a $15 trillion total addressable market. Around $9 billion of this total addressable market is in Europe, which has a highly fragmented market that offers attractive risk-adjusted returns.

Should you buy stock in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $445,833!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,402,153!*

Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of September 5, 2026.

Keith Speights has positions in AbbVie, Enbridge, and Realty Income. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, Enbridge, and Realty Income. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Markets in 2026: Will gold, Bitcoin, and the U.S. dollar make history again? — These are how leading institutions thinkAfter a turbulent 2025, what lies ahead for commodities, forex, and cryptocurrency markets in 2026?
Author  Insights
Dec 25, 2025
After a turbulent 2025, what lies ahead for commodities, forex, and cryptocurrency markets in 2026?
placeholder
Gold rebounds above $4,350 as US Dollar, Treasury yields slipGold price (XAU/USD) rebounds from a nearly one-month low to around $4,385 during the early Asian session on Thursday. The precious metal edges higher as the ‌US Dollar (USD) and Treasury yields retreat from recent highs.
Author  FXStreet
Sep 03, Thu
Gold price (XAU/USD) rebounds from a nearly one-month low to around $4,385 during the early Asian session on Thursday. The precious metal edges higher as the ‌US Dollar (USD) and Treasury yields retreat from recent highs.
placeholder
Gold rebounds past $4,400 as rate-hike odds cool ahead of NFPGold is back above $4,400 after weak ADP data cut September rate-hike odds to ~58%. XAU/USD rebounded from Wednesday's $4,282 low; Friday's NFP is the next catalyst.
Author  Irene Q.
Sep 03, Thu
Gold is back above $4,400 after weak ADP data cut September rate-hike odds to ~58%. XAU/USD rebounded from Wednesday's $4,282 low; Friday's NFP is the next catalyst.
placeholder
Gold rebounds above $4,450 as Waller tempers Fed rate hike bets ahead US jobs dataGold price (XAU/USD) gains momentum to around $4,470 during the early Asian session on Friday. The precious metal extended its recovery as Federal Reserve (Fed) rate hike bets ease. All eyes will be on the US August Nonfarm Payrolls (NFP) report, which is due later on Friday. 
Author  FXStreet
Yesterday 01: 32
Gold price (XAU/USD) gains momentum to around $4,470 during the early Asian session on Friday. The precious metal extended its recovery as Federal Reserve (Fed) rate hike bets ease. All eyes will be on the US August Nonfarm Payrolls (NFP) report, which is due later on Friday. 
placeholder
Yen hits one-month high on BOJ September-hike bets; AUD/JPY cracks support as carry unwindsUSD/JPY has tumbled from the 160 area to a one-month low near 155.2 in two sessions as Bank of Japan hike bets for the Sept 17-18 meeting intensify. AUD/JPY has broken below 112.7, flagging carry-trade stress. A test of 155.21 - and then 153 - is now in focus.
Author  Suzie
Yesterday 06: 52
USD/JPY has tumbled from the 160 area to a one-month low near 155.2 in two sessions as Bank of Japan hike bets for the Sept 17-18 meeting intensify. AUD/JPY has broken below 112.7, flagging carry-trade stress. A test of 155.21 - and then 153 - is now in focus.
goTop
quote